Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Type 2 innate immunity promotes the development of pulmonary fibrosis in Hermansky-Pudlak syndrome
Parand Sorkhdini, … , Bernadette R. Gochuico, Yang Zhou
Parand Sorkhdini, … , Bernadette R. Gochuico, Yang Zhou
Published October 15, 2024
Citation Information: JCI Insight. 2024;9(22):e178381. https://doi.org/10.1172/jci.insight.178381.
View: Text | PDF
Research Article Immunology Pulmonology

Type 2 innate immunity promotes the development of pulmonary fibrosis in Hermansky-Pudlak syndrome

  • Text
  • PDF
Abstract

Hermansky-Pudlak syndrome (HPS), particularly types 1 and 4, is characterized by progressive pulmonary fibrosis, a major cause of morbidity and mortality. However, the precise mechanisms driving pulmonary fibrosis in HPS are not fully elucidated. Our previous studies suggested that CHI3L1-driven fibroproliferation may be a notable factor in HPS-associated fibrosis. This study aimed to explore the role of CHI3L1-CRTH2 interaction on type 2 innate lymphoid cells (ILC2s) and explored the potential contribution of ILC2-fibroblast crosstalk in the development of pulmonary fibrosis in HPS. We identified ILC2s in lung tissues from patients with idiopathic pulmonary fibrosis and HPS. Using bleomycin-challenged WT and Hps1–/– mice, we observed that ILC2s were recruited and appeared to contribute to fibrosis development in the Hps1–/– mice, with CRTH2 playing a notable role in ILC2 accumulation. We sorted ILC2s, profiled fibrosis-related genes and mediators, and conducted coculture experiments with primary lung ILC2s and fibroblasts. Our findings suggest that ILC2s may directly stimulate the proliferation and differentiation of primary lung fibroblasts partially through amphiregulin-EGFR–dependent mechanisms. Additionally, specific overexpression of CHI3L1 in the ILC2 population using the IL-7Rcre driver, which was associated with increased fibroproliferation, indicates that ILC2-mediated, CRTH2-dependent mechanisms might contribute to optimal CHI3L1-induced fibroproliferative repair in HPS-associated pulmonary fibrosis.

Authors

Parand Sorkhdini, Kiran Klubock-Shukla, Selena Sheth, Dongqin Yang, Alina Xiaoyu Yang, Carmelissa Norbrun, Wendy J. Introne, Bernadette R. Gochuico, Yang Zhou

×

Figure 1

ILC2s are increased in human HPS lungs.

Options: View larger image (or click on image) Download as PowerPoint
ILC2s are increased in human HPS lungs.
(A) ILC2 staining in human lung ...
(A) ILC2 staining in human lung tissues. Anti-GATA3, -CD90/Thy1, and a cocktail of 4 antibodies against CD3, CD56, CD20, and CD79α were employed to stain human lung tissues in normal individuals, idiopathic pulmonary fibrosis (IPF) patients, and HPS patients. ILC2s are identified as GATA3+CD90/Thy1+, and antibody cocktail–negative cells (purple cells). The corresponding phase-contrast image shows lung tissue architecture in normal individuals, and pathologic changes in IPF and HPS lungs. (B) Counting of ILC2s (normalized per area) under ×40 magnification using an immunofluorescence microscope. Values are mean ± SEM with a minimum of 4 samples in each group. Comparisons between groups were conducted by 2-way ANOVA with Bonferroni’s post hoc test. ***P ≤ 0.001. Scale bars: 20 μm.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts